GSK and MMV Launch Phase III Trials of Tafenoquine for Malaria

GSK and Medicines for Malaria Venture (MMV) have begun a large-scale Phase III clinical program to assess the effectiveness and safety of tafenoquine in treating and preventing relapses of Plasmodium vivax malaria. Tafenoquine is an investigational medicine specifically targeting the dormant and recurrent stages of P. vivax malaria, which is prevalent in Asia, Latin America, and the Horn of Africa.

The Phase III program includes two randomized, double-blind studies. The "DETECTIVE" study will evaluate tafenoquine's efficacy and safety when co-administered with chloroquine for the radical cure of P. vivax malaria. The "GATHER" study will compare tafenoquine's safety and efficacy against primaquine, the current sole approved treatment for preventing P. vivax malaria relapses. Tafenoquine has not yet received regulatory approval anywhere globally.

P. vivax malaria poses a significant public health challenge, capable of causing repeated bouts of illness due to its dormant liver stage. Treatment challenges have been considerable, as existing therapies are not always effective or can cause side effects. According to Dr. Timothy Wells, Chief Scientific Officer at MMV, tafenoquine has the potential to significantly reduce the burden of malaria and contribute to its elimination.

GSK is committed to combating malaria as part of its broader efforts against developing world diseases. The company collaborates with multiple partners, including MMV, to develop new medicines. The development of tafenoquine represents another step in the pursuit of providing more effective and safer treatments for various forms of malaria.